AZD9150, a next-generation antisense oligonucleotide inhibitor of <i>STAT3</i> with early evidence of clinical activity in lymphoma and lung cancerDavid S. Hong, A. Robert MacLeod, Razelle Kurzrock et al.|Science Translational Medicine|2015Cited by 438
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trialMatthew J. Reilley, David S. Hong, Patricia McCoon et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 286
Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II StudyAnas Younes, Andreas Engert, Anna Sureda et al.|Journal of Clinical Oncology|2012Cited by 261
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in LymphomaPatrizia Mondello, Michael R. Green, Anas Younes et al.|Cancer Discovery|2020Cited by 159
Induction of Cell Cycle Arrest and Apoptosis by the Proteasome Inhibitor PS-341 in Hodgkin Disease Cell Lines Is Independent of Inhibitor of Nuclear Factor-κB Mutations or Activation of the CD30, CD40, and RANK ReceptorsBei Zheng, Anas Younes|Clinical Cancer Research|2004Cited by 109